During the past decade, Azienda Ospedaliero-Universitaria di Cagliari conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 5 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 3 clinical trials were completed. i.e. 17.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Ospedaliero-Universitaria di Cagliari" #1 sponsor was "University of Cagliari" with 6 trials, followed by "Bayer" with 3 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored, "Società Italiana Talassemie ed Emoglobinopatie" with 3 trials sponsored and "Amgen" with 3 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliero-Universitaria di Cagliari" #1 collaborator was "Campus Bio-Medico University" with 1 trials as a collaborator, "Cattedra di Endocrinochirurgia, Università di Verona" with 1 trials as a collaborator, "Dott. Gian Luigi Canu" with 1 trials as a collaborator, "Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente" with 1 trials as a collaborator and "Gruppo Oncologico Italia Meridionale" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliero-Universitaria di Cagliari" are "Psoriasis" (5 trials), "Arthritis, Psoriatic" (2 trials), "Thyroid Cancer" (2 trials), "Anemia" (1 trials) and "Attention Deficit Hyperactivity Disorder (ADHD)" (1 trials). Many other conditions were trialed in "Azienda Ospedaliero-Universitaria di Cagliari" in a lesser frequency.

Most popular intervention types in "Azienda Ospedaliero-Universitaria di Cagliari" are "Drug" (18 trials), "Other" (8 trials), "Procedure" (4 trials), "Diagnostic Test" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Guselkumab" (3 trials), "Thyroidectomy" (2 trials), "Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)" (1 trials) and "Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Ospedaliero-Universitaria di Cagliari" are 31 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Azienda Ospedaliero-Universitaria di Cagliari". 1 are not yet recruiting, 9 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Azienda Ospedaliero-Universitaria di Cagliari, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Ospedaliero-Universitaria di Cagliari, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".

Azienda Ospedaliero-Universitaria di Cagliari has several departments that took part in Clinical trials: "A.O.U. Cagliari-P.O. Monserrato;U.O. Oncologia" - 6 trials, "Policlinico di Monserrato U.O.C. Endocrinologia e Diabetologia" - 2 trials